Analysts have been eager to weigh in on the Healthcare sector with new ratings on Momenta Pharma (NASDAQ:MNTA) and Endo International (NASDAQ:ENDP).
Momenta Pharma (MNTA)
Momenta Pharma received a Buy rating and a $40 price target from Stifel Nicolaus analyst Derek Archila today. The company’s shares opened today at $18.60.
Archila wrote:
“We attended MNTA’s R&D today, which served as a defining event in the company’s transformation from a biosimilar/generic company to a full fledged biotech, where it discussed its plans around its proprietary pipeline. The negative stock reaction (stock down ~11% vs. ~2%) was largely attributed to its disclosure of additional safety data for its anti-FcRn candidate, M281, which generally looked good and competitive relative to other anti-FcRn programs, in our view, but two items (increases in creatine kinase [CK], reduction in albumin) have caused some uncertainty around its safety profile. Ultimately, neither may be issues in the long run (we discuss in detail below) but recognize this overhang could remain until MNTA generates proof-of-concept data in 2020 with shares being volatile until then.”
According to TipRanks.com, Archila is ranked 0 out of 5 stars with an average return of -7.2% and a 28.9% success rate. Archila covers the Healthcare sector, focusing on stocks such as DBV Technologies SA – American, Rhythm Pharmaceuticals Inc, and Pacira Pharmaceuticals.
Momenta Pharma has an analyst consensus of Moderate Buy, with a price target consensus of $32.
See today’s analyst top recommended stocks >>
Endo International (ENDP)
Mizuho Securities analyst Irina Rivkind Koffler reiterated a Hold rating on Endo International today. The company’s shares opened today at $17.34, close to its 52-week high of $18.16.
Rivkind Koffler noted:
“We are raising our PT to $18 from $17 on higher out-year estimates. We reiterate our Neutral rating because of uncertainty about the ongoing opioid litigation, but not because of any business fundamentals (which we view as robust).”
According to TipRanks.com, Koffler is a 5-star analyst with an average return of 9.4% and a 44.0% success rate. Koffler covers the Healthcare sector, focusing on stocks such as Bausch Health Companies Inc, Eagle Pharmaceuticals Inc, and Supernus Pharmaceuticals.
Currently, the analyst consensus on Endo International is a Moderate Buy with an average price target of $16.54.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
